TODAY’S NEWS
Takeda to move forward with new alogliptin study – Takeda Pharmaceutical Co says it is all set to start an additional clinical trial demanded by US regulators on alogliptin, its investigational type 2 diabetes drug. The Japanese drugmaker noted that the US Food and Drug Administration has agreed to the study design for a cardiovascular outcomes trial, titled EXAMINE for alogliptin, a selective dipeptidyl peptidase IV inhibitor (DPP-4) inhibitor also known as SYR-322. The study will involve 5,400 type 2 diabetes patients at around 1,000 facilities in the USA, Europe and Asia…more
Genzyme leukemia drug study: hard to interpret – “The lack of a randomized study combined with the heterogeneous patient population regarding AML prognostic factors makes interpretation of the study results difficult.” Food and Drug Administration staff said in an analysis prepared for the panel, which meets Tuesday…more
Smoker’s lung treatment: coming soon from Forest and Nycomed? – An experimental once-daily tablet from Nycomed and Forest Laboratories improves lung function in people with “smoker’s lung” and may be a useful add-on to conventional inhaled drugs, experts said on Friday. Privately owned Swiss drugmaker Nycomed, which is working towards a multibillion-dollar flotation, hopes Daxas will reach the market in 2010 and believes it has blockbuster potential…more
Pharmas that got hurt by debt shenanigans, including BMS and Teva. And, a rash of drug heists.
RECOMMENDED
Social Media monitoring. It’s one thing to launch a social media app. It’s another to actively monitor comments, discussions, and manage forums. If you’re looking at this need, the Impactiviti Partner Network can help. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for information and recommendations!
Younger folks just don’t want to take their cholesterol meds.
JUST FOR FUN
A Danger sign you don’t want to see…
———-
Subscribe to the Impactiviti blog via e-mail
Connect with Steve Woodruff
Leave a Reply